Abate Kristin 4
4 · Karyopharm Therapeutics Inc. · Filed Jan 22, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) Chief Accounting Officer Kristin Abate Sells 265 Shares
What Happened Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics (KPTI), sold 265 shares on 2026-01-21 at $5.96 per share, generating proceeds of $1,579. The filing indicates this was a broker-assisted sale to satisfy withholding tax liability from the vesting of restricted stock units and was not a discretionary trade.
Key Details
- Transaction type: Sale (Code S)
- Date: 2026-01-21; Price: $5.96 per share; Total proceeds: $1,579
- Footnote: Sale effected under a durable automatic sale instruction plan adopted May 27, 2021; sale to cover tax withholding on RSU vesting (not discretionary)
- Filing: Reported on Form 4 filed 2026-01-22 (timely)
- Shares owned after transaction: Not specified in the information provided
Context Sales to cover tax withholding on vested restricted stock units are routine and reflect tax obligations rather than a proactive decision to reduce holdings. This small, single transaction ($1.6k) should be viewed differently than a voluntary large insider sale; purchases or voluntary sales usually carry more interpretive weight for investor sentiment.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-01-21$5.96/sh−265$1,579→ 22,580 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.